Pharmacogenomics and pharmacogenetics of thiazolidinediones: role in diabetes and cardiovascular risk factors.
Pharmacogenomics
Della-Morte, David D; Palmirotta, Raffaele R; Rehni, Ashish K AK; Pastore, Donatella D; Capuani, Barbara B; Pacifici, Francesca F; De Marchis, Maria Laura ML; Dave, Kunjan R KR; Bellia, Alfonso A; Fogliame, Giuseppe G; Ferroni, Patrizia P; Donadel, Giulia G; Cacciatore, Francesco F; Abete, Pasquale P; Dong, Chuanhui C; Pileggi, Antonello A; Roselli, Mario M; Ricordi, Camillo C; Sbraccia, Paolo P; Guadagni, Fiorella F; Rundek, Tatjana T; Lauro, Davide D
Halaschek-Wiener, Julius J; Amirabbasi-Beik, Mahsa M; Monfared, Nasim N; Pieczyk, Markus M; Sailer, Christian C; Kollar, Anita A; Thomas, Ruth R; Agalaridis, Georgios G; Yamada, So S; Oliveira, Lisa L; Collins, Jennifer A JA; Meneilly, Graydon G; Marra, Marco A MA; Madden, Kenneth M KM; Le, Nhu D ND; Connors, Joseph M JM; Brooks-Wilson, Angela R AR
Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone.
The Journal Of Clinical Endocrinology And Metabolism
Florez, Jose C JC; Jablonski, Kathleen A KA; Sun, Maria W MW; Bayley, Nick N; Kahn, Steven E SE; Shamoon, Harry H; Hamman, Richard F RF; Knowler, William C WC; Nathan, David M DM; Altshuler, David D; ,
Sequence variation in PPARG may underlie differential response to troglitazone.
Diabetes
Wolford, Johanna K JK; Yeatts, Kimberly A KA; Dhanjal, Sharanjeet K SK; Black, Mary Helen MH; Xiang, Anny H AH; Buchanan, Thomas A TA; Watanabe, Richard M RM